BLRX - BioLineRx

-

$undefined

N/A

(N/A)

BioLineRx NasdaqCM:BLRX BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Location: Modi’in Technology Park, Hevel Modi'in, 7177871, Israel | Website: https://www.biolinerx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

7.229B

Cash

19.56M

Avg Qtr Burn

-10.97M

Short % of Float

0.01%

Insider Ownership

4.67%

Institutional Own.

0.25%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Motixafortide (BL-8040) w/ zimberelimab Details
Pancreatic cancer, Cancer, Solid tumor/s

Phase 2b

Initiation

Phase 2

Data readout

Motixafortide (BL-8040) Details
Blood disorder, Sickle cell disease

Phase 1

Data readout

Phase 1

Update

AGI-134 Details
Solid tumor/s, Cancer

Failed

Discontinued

Failed

Discontinued

Motixafortide (BL-8040) (CXCR4 antagonist) Details
Pancreatic cancer, Solid tumor/s, Cancer

Failed

Discontinued